You just read:

Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

News provided by

Protalix BioTherapeutics, Inc.

May 11, 2020, 06:50 ET